A5011128140- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- AI in cancer detection
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Renal cell carcinoma treatment
- Plant-Microbe Interactions and Immunity
- Cardiac Ischemia and Reperfusion
- MRI in cancer diagnosis
- Bone Metabolism and Diseases
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cancer Cells and Metastasis
- Prostate Cancer Diagnosis and Treatment
- Cardiac Arrest and Resuscitation
Binzhou Medical University
2023-2025
Binzhou University
2023-2025
Zhejiang Chinese Medical University
2024-2025
Qingdao University
2022-2025
Yuhuangding Hospital
2022-2025
Henan Polytechnic University
2024
Jiangxi University of Traditional Chinese Medicine
2024
Zhengzhou University
2024
Shaanxi University of Chinese Medicine
2024
Zhejiang Pharmaceutical College
2024
BackgroundMetastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbations. The aim of this study was to identify cell free DNA- (cfDNA-) based alterations and their associations with outcomes in metastatic cancer.MethodsIn longitudinal prospective cohort plasma cfDNA/circulating tumor DNA (ctDNA) analyzed before, during, after androgen deprivation therapy (ADT) 4 independent patient groups ranging from untreated hormone sensitive...
Abstract Purpose: Clinical biomarkers to identify patients unlikely benefit from CDK4/6 inhibition (CDK4/6i) in combination with endocrine therapy (ET) are lacking. We implemented a comprehensive circulating tumor DNA (ctDNA) analysis genomic features for predicting and monitoring treatment resistance. Experimental Design: ctDNA was isolated 216 plasma samples collected 51 hormone receptor–positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC) on phase II trial of palbociclib...
Genomic alterations in DNA damage response (DDR) genes are common metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment is vital for optimising clinical outcomes.
Abstract Background Liquid biopsy has emerged as a non‐invasive method for real‐time cancer monitoring especially in genitourinary (GU) oncology. Most current studies utilize panel‐based molecular profiling ranging from 50–600 genes; however, comprehensive exome‐wide of real‐world patient samples been lacking. Methods Over 2000 liquid were analyzed this study, including urine early‐stage bladder and plasma prostate, lung, breast, esophageal, head neck cancers, among others. Cell‐free DNA...
Early predicting response before neoadjuvant chemotherapy (NAC) is crucial for personalized treatment plans locally advanced breast cancer patients. We aim to develop a multi-task model using multiscale whole slide images (WSIs) features predict the NAC more finely. This work collected 1,670 training and validation sets, internal testing external prospective sets of weakly-supervised deep learning-based (DLMM) in pCR NAC. Our approach models two-by-two feature interactions across scales by...
Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs plasma cell-free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition PTEN-deficient mCRPC, we profiled pathway aberrations patients with mCRPC using a novel cfDNA assay optimized for CNV detection.
The correlations between circulating tumour DNA (ctDNA)-derived genomic markers and treatment response survival outcome in Chinese patients with advanced breast cancer (ABC) have not been extensively characterized.Blood samples from 141 ABC who underwent first-line standard Peking University Cancer Hospital were collected. A next-generation sequencing based liquid biopsy assay (PredicineCARE) was used to detect somatic mutations copy number variations (CNVs) ctDNA. subset of matched blood...
Accurate detection and classification of breast lesions in early stage is crucial to timely formulate effective treatments for patients. We aim develop a fully automatic system detect classify using multiple contrast-enhanced mammography (CEM) images.In this study, total 1,903 females who underwent CEM examination from three hospitals were enrolled as the training set, internal testing pooled external set prospective set. Here we developed CEM-based multiprocess (MDCS) perform task lesions....
Accurate diagnosis of breast lesions and discrimination axillary lymph node (ALN) metastases largely depend on radiologist experience. To develop a deep learning-based whole-process system (DLWPS) for segmentation ALN metastasis. Retrospective. 1760 patients, who were divided into training validation sets (1110 patients), internal (476 external (174 patients) test sets. 3.0T/dynamic contrast-enhanced (DCE)-MRI sequence. DLWPS was developed using classification models. The DLWPS-based model...
Exercise training offers cardioprotection against ischemia and reperfusion (I/R) injury. However, few essential signals have been identified to underscore the protection from In present study, we hypothesized that exercise-induced acceleration of myocardial tissue oxygenation recovery contributes this protection. C57BL/6 mice (4 weeks old) were trained on treadmills for 45 min/day at a treading rate 15 m/min 8 weeks. At end 8-week exercise training, underwent 30-min left anterior descending...
Abstract Docetaxel chemotherapy is a standard treatment option for metastatic castrate resistant prostate cancer (mCRPC) patients. To date, the genomic perturbations underlying emergence of resistance in mCRPC patients during have not been fully characterized. Previous studies established that AR , TP53 RB1 and PTEN gene alterations are frequent at this stage progression but associated with poor outcome. However, clonal dynamics these key driver genes described. Toward goal, we performed...
Purpose: The authors aimed to establish an artificial intelligence (AI)-based method for preoperative diagnosis of breast lesions from contrast enhanced mammography (CEM) and explore its biological mechanism. Materials methods: This retrospective study includes 1430 eligible patients who underwent CEM examination June 2017 July 2022 were divided into a construction set ( n =1101), internal test =196), pooled external =133). AI model adopted RefineNet as backbone network, attention...
Poor outcomes have been widely reported for younger vs. older breast cancer patients, but whether this is due to age itself or the enrichment of aggressive clinical features remains controversial. We evaluated clinicopathologic characteristics and genomic profiles real-world hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic (MBC) patients examine determinants outcome in a single subtype undergoing treatment same clinic.This study included presenting at Peking University Cancer...
PURPOSE To determine prognostic and predictive clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) castrate-resistant (mCRPC) on the basis of a combination plasma-derived genomic alterations lipid features longitudinal cohort patients with advanced cancer. METHODS A multifeature classifier was constructed to predict using plasma-based detected 120 genes 772 lipidomic species as informative 71 mHSPC 144 mCRPC. Outcomes interest were collected over 11 years follow-up....
Current liquid biopsy assays lack sufficient sensitivity to detect copy number loss, which limits the interrogation of critical tumor suppressor gene deletions during cancer progression and treatment. Here we describe a assay with improved for detection loss in blood samples low levels circulating DNA, demonstrate its utility by profiling PTEN , RB1 TP53 genetic metastatic prostate patients.
1. This study determined the effects of (E)-3-(2-(4-(3-(2,4-dimethoxyphenyl)acryloyl)phenoxy)ethoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one (EDACO) on differentiation Gaoyou duck embryonic osteoclasts cultured in vitro. 2. Bone marrow mononuclear cells (BM-MNC) were collected from 23-d-old embryos and induced by macrophage colony-stimulating factor receptor activator nuclear κB ligand presence EDACO at different concentrations (i.e. 10, 20, 40, 80 160 µM)....